Amneal Pharmaceuticals, Inc. (AMRX) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 10 Buy, 6 Hold.
The consensus price target is $16.00 (low: $15.00, high: $17.00), representing an upside of 22% from the current price $13.12.
Analysts estimate Earnings Per Share (EPS) of $0.61 and revenue of $2.77B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.38 vs est $0.61 (missed -162%). 2025: actual $0.23 vs est $0.80 (missed -71.2%). Analyst accuracy: 0%.
AMRX Stock — 12-Month Price Forecast
$16.00
▲ +21.95% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Amneal Pharmaceuticals, Inc., the average price target is $16.00, with a high forecast of $17.00, and a low forecast of $15.00.
The average price target represents a +21.95% change from the last price of $13.12.
Highest Price Target
$17.00
Average Price Target
$16.00
Lowest Price Target
$15.00
AMRX Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Amneal Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — AMRX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.38
vs Est $0.61
▼ 261.2% off
2025
Actual $0.23
vs Est $0.80
▼ 247.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — AMRX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.794B
vs Est $2.770B
▲ 0.9% off
2025
Actual $3.019B
vs Est $3.012B
▲ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
